Bold Therapeutics Inc.’s Post

Excited to share our latest research on "Discovery of Novel Pyrazolo[1,5-a]pyrimidine Derivatives as Potent Reversal Agents Against ABCB1-Mediated Multidrug Resistance." In this study, we've identified a promising compound, 16q, that significantly enhances the sensitivity of multidrug-resistant cancer cells to chemotherapy. By effectively binding and stabilizing the ABCB1 protein, 16q restores the efficacy of paclitaxel, paving the way for more effective cancer treatments. Check out the full abstract below! #CancerResearch #DrugResistance #Chemotherapy #MolecularBiology #PharmaceuticalSciences #Cancer

“63rd SPSR Webinar on Heteronemin’s Cytotoxic Potential and Action Mechanism against Prostate Cancer Cells, LNcap and PC3'" hosted by the Society of Pharmaceutical Sciences and Research (SPSR). Key Details: - Date: Sunday, September 1, 2024 - Time: 11:00 AM IST onwards. - No registration fees - Last date of Registration - August 31, 2024, 5 PM IST. Our esteemed speaker for this event is Prof. Mohamed El-Shazly, Professor, Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, 11566, Cairo, Egypt. The 63rd SPSR Webinar focuses on the study of Heteronemin, a marine sesterterpenoid-type natural product. This compound has shown significant cytotoxic effects against LNcap and PC3 prostate cancer cells. Heteronemin has been observed to induce apoptosis, disrupt mitochondrial membrane potential, and promote calcium release in a dose-dependent manner. It also inhibits the enzymatic activity of topoisomerase IIα. In a xenograft animal model, the tumor size was significantly suppressed by about 51.9% with Heteronemin treatment. This webinar aims to further explore the antitumor mechanism of Heteronemin and its potential as a potent anticancer agent in clinical therapy. Convener - Mrs. Monika Sabharwal, Founder and National Secretary SPSR SPSR is recognized for its captivating webinars, solidifying its position as a premier platform for professional development in the pharmaceutical industry. We are confident that this webinar will continue to reflect our high standards, offering significant insights from an esteemed speaker. Let us seize this opportunity to acquire new information, engage meaningfully, and advance our field. Welcome, and we anticipate a rewarding session for all attendees. Thank you for being here. Webinar Access: The webinar will be broadcast live on SPSR's YouTube Channel. To join us for this event, we kindly request you to subscribe to the Society of Pharmaceutical Sciences and Research (SPSR) YouTube Channel by clicking on the following link:     / societyofpharmaceuticalsciencesandresearch  Registration: To secure your spot and receive updates about the webinar, we request you to register by filling out the required details in the registration form provided. Please click on the following link to access the registration form: https://lnkd.in/dBNmuHzh Webinar Feedback link - Note - Make sure to fill out the feedback form during the live session to claim your participant certificate! Join this channel to get access to perks:     / @societyofpharmaceuticalsci4800  For more updates you may join the SPSR WhatsApp channel, click the link below and follow. https://lnkd.in/dxgyQBSC...

Cytokine therapy in oncology is coming of age. Interleukin-12 (IL-12), a cell signaling molecule that helps the immune system identify and respond to threats, has been tried before but caused unacceptable toxicity. Xilio developed a "stealth" IL-12 molecule, where, rather than activating immune responses all over the body, IL-12 is activated by the tumor microenvironment and thus only actives signaling within tumors. Early data from their phase 1 trial (n=9 patients) did not reach a dose-limiting toxicity, even at almost 100x the dose-limit of unmodified recombinant IL-12. I'm looking forward to more advances in targeted cytokine therapies from Xilio Therapeutics, Inc. and others. Excellent work! #oncology #cytokines #cancer #immuneSystem #CytokineTherapy https://buff.ly/48w0WDy +++ 👋 I’m Chris, a passionate medical writer, strategist, and founder of Quill Science LLC dedicated to bridging the gap between science and its impact with accurate and compelling narratives. 🌐 For a scientific partner led by curiosity and desire to improve health, please check out Quill Science and book a discovery call: https://buff.ly/3TNRiY5

A good method for lead optimization.

MAIA Biotechnology (NYSE: MAIA) Reveals New #Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer. Read the press release here: https://bit.ly/4aMMFlZ #NSCLC #Oncology #OncNews #ASCO24 #ClinicalResearch

Our TRC research chemicals were used in recent research conducted by scientists at the University of Leipsic, in which nanomaterials carrying third-generation chemotherapy and anti-inflammatories showed promise in models of breast cancer. The application of nanomaterials to the development of novel cancer drug formulations has shown huge promise for increasing efficacy, reducing toxicity and enabling targeted delivery of combination therapies. Read the full article in the journal Advanced Therapeutics at: https://okt.to/FC8boW TRC is your trusted partner in target identification and drug development. Explore our extensive range of industry-leading research chemicals and how we can support your research interests: https://okt.to/4pM3ld #ProductCitation #ResearchChemicals #BreastCancer #Oncology #ScienceForASaferWorld

Mythic Therapeutics, Inc. announced promising initial results from the Phase 1 KisMET-01 study of MYTX-011, a novel cMET-targeting ADC, in treating advanced or metastatic non-small cell lung cancer (NSCLC). The study, presented at the ASCO Annual Meeting, showed MYTX-011 was well-tolerated with no dose-limiting toxicity and demonstrated nearly dose-proportional pharmacokinetics. The study continues to assess safety, tolerability, and preliminary anti-tumor activity, with further efficacy data to be presented in the future. The findings offer hope for patients with diverse cMET expression levels. #HemiBio Brian Fiske https://lnkd.in/epvx2gPC

We recently presented data at #NACLC23 from our ongoing Phase 2 KUNPENG and SPARTA trials, featuring the ORR of vebreltinib by gene copy number (GCN) for the first time in NSCLC patients with MetExon14 skipping mutation. These promising results demonstrate vebreltinib's potential to treat patients with this challenging cancer, as well as its differentiation from other cMET inhibitors. Learn more in this week's press release below. #Oncology #CancerResearch

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers "Sonnet BioTherapeutics reports successful safety and tolerability for SON-1010. This breakthrough could revolutionize cancer treatment. Learn more about the potential for innovative oncology solutions!" #SonnetBioTherapeutics #CancerTreatment #SON1010 #HealthcareInnovation #Oncology #Biotherapy #pharma #biotech #pharmiwebcom

eFFECTOR Therapeutics, Inc. said it will halt development of tomivosertib in #lungcancer after the MNK inhibitor failed to significantly improve survival. https://lnkd.in/d3cMqd4y #biotechnology #cancer #clinicalresearch #clinicaltrials #drugdevelopment #oncology #pharmaceuticals